Sources and Guidelines Referenced

This clinical explainer is based on published clinical practice guidelines and high-evidence consensus statements from leading international authorities in reproductive medicine: European Society of Human Reproduction and Embryology (ESHRE Guideline: Recurrent Pregnancy Loss, 2023 update); American Society for Reproductive Medicine (ASRM Practice Committee Opinion on Definitions and Evaluation of Recurrent Pregnancy Loss, 2020/2024); Royal College of Obstetricians and Gynaecologists (RCOG Green-top Guideline No. 17: Investigation and Management of Couples with Recurrent Miscarriage, 2023); American College of Obstetricians and Gynecologists (ACOG Practice Bulletin No. 200: Early Pregnancy Loss, 2018, reaffirmed 2023); and key landmark clinical trials including the PROMISE (Coomarasamy et al., NEJM, 2015) and PRISM (Coomarasamy et al., NEJM, 2019) studies.

Recurrent Pregnancy Loss Clinic: A Comprehensive Patient Guide

1. Definition and Medical Identity

A recurrent pregnancy loss clinic is a specialized medical facility dedicated to evaluating, diagnosing, and managing individuals and couples experiencing multiple failed pregnancies. Led by subspecialists in reproductive endocrinology and maternal-fetal medicine, these clinics provide centralized diagnostic protocols to identify underlying maternal, paternal, or embryonic causes of repeated loss.

The formal medical definition of recurrent pregnancy loss (RPL) historically required three consecutive pregnancy losses prior to 20 to 24 weeks of gestation. Modern clinical practice guidelines from the American Society for Reproductive Medicine (ASRM) and the European Society of Human Reproduction and Embryology (ESHRE) define RPL as two or more clinical pregnancy losses. A clinical pregnancy loss is confirmed by ultrasound or histopathological examination, distinguishing it from an isolated biochemical pregnancy (a temporary rise in human chorionic gonadotropin without clinical visualization).

RPL clinics operate as specialized diagnostic and therapeutic hubs within academic medical centers and specialized fertility units. Their core purpose is to replace empirical, unproven treatments with evidence-based interventions tailored to verified biological mechanisms.

2. The Underlying Condition or Need

Recurrent pregnancy loss is a distinct clinical entity separate from sporadic early pregnancy loss. While a single miscarriage occurs in 15% to 20% of all recognized pregnancies—most commonly due to unpredictable genetic errors during fertilization—recurrent loss affects 1% to 2% of reproductive-aged couples and warrants structured investigation.

The biological problem in RPL involves multi-systemic physiological breakdowns that disrupt normal embryonic implantation, placental development, or fetal maintenance. The main clinical etiologies are categorized into six major domains:

• Parental Chromosomal Rearrangements: Structural chromosomal variations in either biological parent, such as balanced reciprocal or Robertsonian translocations, which produce unbalanced gametes.
• Uterine Anatomical Abnormalities: Congenital uterine malformations (e.g., septate uterus) or acquired structural lesions (e.g., submucosal uterine fibroids, intra-uterine adhesions or Asherman syndrome, endometrial polyps).
• Endocrine Dysfunction: Poorly controlled thyroid disease (hypothyroidism or hyperthyroidism), uncontrolled diabetes mellitus, hyperprolactinemia, or polycystic ovary syndrome (PCOS).
• Autoimmune and Thrombophilic Factors: Acquired autoimmune conditions, specifically antiphospholipid syndrome (APS), which lead to microvascular thrombosis, impaired trophoblast invasion, and placental infarction.
• Immunological and Environmental Variables: Altered endometrial receptivity, aberrant maternal-fetal immune tolerance, metabolic dysregulation, and high oxidative stress.
• Unexplained Etiology: Cases in which comprehensive standard testing shows normal results, representing approximately 50% of evaluated couples (ESHRE 2023).

Without structured evaluation, patients may undergo repeated losses, leading to physical morbidity, delayed parenthood, and substantial emotional trauma. A specialized clinic aims to establish an early diagnosis and reduce further miscarriages.

3. How the Treatment Works — Mechanism

An RPL clinic functions by applying systematic diagnostic protocols to identify targetable pathology, followed by etiology-specific medical or surgical management. Rather than offering a single standard procedure, the clinic acts as an investigative and therapeutic framework.

When a patient enters an RPL clinic, clinicians analyze the biological interface between the expanding blastocyst and the maternal decidua (the specialized uterine lining of pregnancy). Successful pregnancy requires precise mechanical, hormonal, genetic, and immunologic coordination:

• Genetic Integrity: Ensuring normal embryonic chromosomal count (euploidy). If a parent carries a balanced translocation, meiosis can produce gametes with missing or extra chromosomal segments, leading to early lethality.
• Uterine Architecture and Perfusion: The uterine cavity must present a symmetrical, well-vascularized environment. A uterine septum consists of fibromuscular tissue with inadequate blood flow; when an embryo implants on the septum, nutrient supply is compromised, triggering early pregnancy loss.
• Endocrine Equilibrium: Thyroid hormones and progesterone regulate endometrial receptivity. Inadequate progesterone stimulation during the luteal phase prevents proper decidualization, impairing firm attachment of the trophoblast.
• Hemostatic and Immunologic Balance: Antiphospholipid antibodies target cell-surface phospholipids on trophoblast cells, directly causing cellular damage, triggering local inflammation, and forming microthrombi in developing placental vessels. Target-directed therapy uses anticoagulants to prevent this cascade.

By determining which biological domain is impaired, the clinic provides targeted treatments—such as surgical septum resection, targeted hormone regulation, or antithrombotic therapy—to restore uterine homeostatic balance.

4. Types and Variations

Clinical care within an RPL clinic is divided into four main care pathways based on medical history, loss patterns, and clinical findings.

The clinician selects the initial management strategy according to guidelines from ESHRE (2023) and ASRM (2020), as outlined in the comparative summary below.

Protocol Category	Target Patient Population	Primary Diagnostic Focus	Core Therapeutic Interventions
Standard Diagnostic Protocol	Patients with 2 consecutive or non-consecutive clinical early losses	Parental karyotyping, 3D pelvic ultrasound, TSH, anti-TPO, antiphospholipid panel	Endocrine normalization, surgical referral for cavity defects, lifestyle optimization
Autoimmune & Antithrombotic Protocol	Patients with verified antiphospholipid antibodies or late pregnancy loss history	Lupus anticoagulant, anticardiolipin, anti-beta-2-glycoprotein I IgG/IgM (repeated at 12 weeks)	Low-dose aspirin (75–100 mg/day) combined with prophylactic low-molecular-weight heparin (LMWH)
Genomic & ART Protocol	Couples with known parental structural chromosome translocations or advanced maternal age	High-resolution parental peripheral blood karyotyping, tissue microarray on miscarried tissue	In vitro fertilization (IVF) with Preimplantation Genetic Testing for Structural Rearrangements (PGT-SR)
Unexplained RPL & Supportive Protocol	Couples with normal diagnostic results across all standard categories	Exclusion of rare abnormalities, endometrial profiling, metabolic markers	Empiric luteal phase micronized progesterone, supportive care, weekly early pregnancy ultrasounds

5. Who the Treatment Is For — Indications

Services at a recurrent pregnancy loss clinic are indicated for individuals or couples meeting specific clinical and diagnostic criteria established by major specialty societies.

Key medical indications include:

• Two or More Documented Losses: Two consecutive or non-consecutive pregnancy losses confirmed by transvaginal ultrasound or histopathology (ASRM 2020; ESHRE 2023).
• Single Late Pregnancy Loss: A single unexplained fetal death after 10–12 weeks of gestation, which warrants immediate investigation for antiphospholipid syndrome or uterine anomalies.
• Known Parental Translocations: Identification of a balanced translocation in either biological parent following genetic testing of a past loss.
• Uterine Structural Abnormalities: Incidental identification of a uterine septum, large submucosal fibroid, or extensive intra-uterine adhesions in a patient with a history of miscarriage.
• Advanced Reproductive Age with Miscarriage History: Females aged 35 or older who have experienced two pregnancy losses, where rapid diagnostic evaluation is critical due to declining ovarian reserve.

Diagnostic evaluation is typically initiated 4 to 6 weeks after complete expulsion or surgical clearance of miscarried tissue to ensure laboratory parameters return to non-pregnant baseline levels.

6. Who the Treatment Is NOT For — Contraindications

While diagnostic screening at an RPL clinic is non-invasive and safe, certain medical conditions and clinical scenarios contraindicate specific invasive tests or medical treatments.

Key clinical contraindications include:

• Active Emergency Obstetric Complications: Patients currently experiencing incomplete miscarriage, heavy hemorrhage, or acute ectopic pregnancy requiring immediate surgical or medical clearance before elective RPL evaluation.
• Uncontrolled Active Infection: Active pelvic inflammatory disease (PID) or acute cervicitis strictly contraindicates invasive uterine cavity imaging, such as saline infusion sonohysterography or hysteroscopy, due to the risk of spreading infection into the peritoneal cavity.
• Severe Uncompensated Systemic Disease: Unstable cardiac, pulmonary, or renal disease requires primary medical stabilization prior to undergoing fertility treatments or subsequent pregnancy attempts.
• Contraindications to Specific Therapeutics: Active major bleeding disorders, history of heparin-induced thrombocytopenia (HIT), or severe allergy to antithrombotic medications preclude low-molecular-weight heparin therapy in antiphospholipid syndrome management.

7. Alternatives and Clinical Comparison

Patients with recurrent pregnancy loss may evaluate several care strategies, ranging from conservative expectant management to advanced assisted reproductive technology (ART).

The table below summarizes alternative clinical pathways compared to dedicated evaluation at a specialized RPL clinic.

Care Strategy	Diagnostic Thoroughness	Level of Invasiveness	Mechanism of Action	Clinical Trade-offs
Specialized RPL Clinic Management	High (Systematic multi-system evaluation)	Low to Moderate (Blood work, outpatient cavity imaging)	Identifies and treats targeted maternal/paternal biological etiologies	Requires time for testing; approximately 50% of cases remain unexplained
Empirical Expectant Management	None (No diagnostic investigation)	None (Natural conception attempts)	Relies on natural biological probability of a normal euploid conception	High risk of repeated loss if treatable maternal factors (e.g., APS, uterine septum) exist
IVF with PGT-A (Aneuploidy Screening)	Moderate (Evaluates embryonic chromosomal status)	High (Ovarian stimulation, transvaginal egg retrieval, embryo biopsy)	Selects chromosomally normal (euploid) embryos for transfer	Invasive and expensive; does not address maternal uterine, thrombotic, or immunologic factors
Empirical Luteal Phase Progesterone Therapy	Low (Focuses solely on hormonal support)	Low (Vaginal or oral progesterone administration)	Supplements endometrial support during early implantation window	Ineffective if loss is driven by parental structural translocations or uterine septa

8. Pre-Treatment Phase

The pre-treatment phase begins with systematic clinical documentation and baseline laboratory preparation. Patients are advised to wait for the return of regular menses following their most recent loss before undergoing definitive laboratory testing.

Key elements of the pre-treatment phase include:

• Comprehensive Medical and Reproductive History: The clinician evaluates loss timing, presence of embryonic cardiac activity prior to loss, tissue histopathology, prior surgical procedures, and personal or family history of venous thromboembolism or autoimmune disease.
• Medical Record Compilation: Gathering genetic reports from miscarried tissue (karyotype or chromosomal microarray analysis), operative reports, and previous pelvic imaging.
• Laboratory Timing Coordination: Scheduling blood tests at appropriate baseline times. Antiphospholipid antibody panels are performed at least 6 weeks post-loss and repeated 12 weeks later to confirm persistence. Hormonal tests (TSH, prolactin, ovarian reserve markers) are performed in the early follicular phase (days 2–4 of the menstrual cycle).
• Parental Counseling: Both biological partners undergo clinical counseling regarding genetic screening pathways and lifestyle optimization prior to initiating diagnostic steps.

9. The Procedure — Step-by-Step Clinical Detail

Evaluation at a recurrent pregnancy loss clinic follows a systematic, multi-step diagnostic process rather than a single procedure. Below is the clinical workflow.

Phase 1: Diagnostic Blood Screening

The patient undergoes targeted blood sampling across five primary categories:

• Parental Karyotyping: Peripheral blood lymphocytes are cultured and analyzed to screen for structural chromosomal anomalies, such as balanced reciprocal or Robertsonian translocations.
• Thrombophilia Testing: Diagnostic screening for acquired antiphospholipid syndrome, including tests for lupus anticoagulant, IgG and IgM anticardiolipin antibodies, and IgG and IgM anti-beta-2-glycoprotein I antibodies. Routine screening for inherited thrombophilia (Factor V Leiden, Prothrombin gene mutation, Protein C/S deficiency) is performed selectively based on personal or family history of thrombosis (ESHRE 2023).
• Endocrine Assessment: Quantitative measurement of TSH, anti-thyroid peroxidase (anti-TPO) antibodies, serum prolactin, glycated hemoglobin (HbA1c), and baseline ovarian reserve markers.
• Immunological Assessment: Evaluation for systemic autoimmune diseases, such as systemic lupus erythematosus, when systemic symptoms are present.

Phase 2: Anatomical Evaluation of the Uterine Cavity

Uterine architecture is assessed using high-resolution imaging techniques during the follicular phase of the menstrual cycle (after menstrual bleeding ceases but prior to ovulation):

• Three-Dimensional Transvaginal Ultrasonography (3D TVUS): The primary diagnostic tool for differentiating congenital uterine malformations, particularly separating a septate uterus from a bicornuate uterus by measuring the internal and external uterine contour.
• Saline Infusion Sonohysterography (SIS): Sterile saline is infused into the endometrial cavity through a thin catheter during ultrasound imaging to clearly outline endometrial polyps, submucosal fibroids, or intra-uterine adhesions.
• Diagnostic Hysteroscopy: Direct endoscopic visualization of the uterine cavity using a micro-camera inserted through the cervix, providing definitive confirmation and potential operative correction of intra-uterine pathology.

Phase 3: Targeted Therapeutic Implementation

Once diagnostics are complete, a personalized treatment plan is developed:

• Surgical Intervention: Hysteroscopic septum resection is performed under short general or sedation anesthesia to remove non-vascularized fibromuscular tissue, restoring standard cavity contour.
• Antithrombotic Therapy: Patients diagnosed with antiphospholipid syndrome initiate low-dose aspirin (75–100 mg daily) prior to conception, adding prophylactic low-molecular-weight heparin (e.g., enoxaparin 40 mg daily) upon confirmation of a positive pregnancy test.
• Endocrine Management: Levothyroxine is prescribed to maintain TSH levels below 2.5 mIU/L prior to and during early pregnancy.

Phase 4: Early Obstetric Surveillance Protocol

When a subsequent pregnancy occurs, the patient enters an intensive monitoring protocol:

• Serial quantitative serum hCG measurements every 48 hours to confirm appropriate doubling time.
• Empiric or indication-based vaginal progesterone supplementation (200–400 mg daily) starting in the luteal phase or upon a positive pregnancy test, per the PRISM trial findings for patients with early bleeding and prior losses.
• Weekly transvaginal ultrasounds from 5–6 weeks through 10–12 weeks of gestation to confirm intra-uterine gestational sac location, yolk sac formation, embryonic length, and cardiac activity.

10. Immediate Post-Procedure Period

Because the RPL clinical pathway consists mainly of outpatient laboratory tests and non-invasive or minimally invasive diagnostic procedures, physical recovery in the immediate post-procedure period is straightforward.

Following outpatient uterine cavity evaluation (3D TVUS or SIS), patients may experience mild pelvic cramping or light vaginal spotting for 12 to 24 hours. Over-the-counter analgesics such as acetaminophen or ibuprofen are typically sufficient to manage discomfort. Normal daily activities, including returning to work, can be resumed immediately.

When diagnostic or operative hysteroscopy is performed under conscious sedation or short general anesthesia, patients remain in a day-surgery recovery unit for 1 to 2 hours until vital signs stabilize. A responsible adult companion must escort the patient home. Pelvic rest (avoiding vaginal tampons, douching, and sexual intercourse) is advised for 3 to 7 days to prevent ascending infection.

11. Recovery — Short and Long Term

Physical, clinical, and psychological recovery timelines differ across diagnostic and therapeutic phases in an RPL clinic.

Short-Term Recovery (Days to Weeks)

• Physical Recovery: Minimal to short. Non-invasive blood work requires no downtime. Minor operative interventions (such as hysteroscopic septum resection) require 2 to 4 days of reduced physical activity, with full recovery within one week.
• Laboratory Results Processing: Complete diagnostic results typically take 2 to 4 weeks. Parental karyotyping and tissue chromosomal microarrays require cell culture and genetic analysis, taking up to 3 to 6 weeks for complete reporting.

Long-Term Management (Months to Subsequent Pregnancy)

• Conception Timing: Patients are typically advised to delay conception for 1 to 2 menstrual cycles following operative uterine procedures to allow proper endometrial healing.
• Early Pregnancy Monitoring: Continuous clinical surveillance spans the first 10 to 12 weeks of a subsequent pregnancy. Once fetal cardiac activity and gestational age are confirmed past 12 weeks, patient care is transitioned to primary obstetric care or maternal-fetal medicine specialists.

12. Risks, Side Effects, and Complications

The diagnostic and therapeutic strategies utilized in an RPL clinic are generally safe, but potential side effects and complications can occur across various procedures and medical protocols.

The risk matrix below details severity categories, expected clinical frequencies, and standardized management protocols.

Severity Level	Potential Complication / Side Effect	Observed Frequency	Clinical Management Strategy
Common / Mild	Transient venous bruising from phlebotomy; uterine cramping and mild spotting following saline infusion sonohysterography or hysteroscopy	10% – 30% of procedures	Patient reassurance, mild oral non-opioid analgesics (acetaminophen), localized warm compresses
Uncommon / Moderate	Localized pelvic infection or endometritis post-hysteroscopy; minor subcutaneous bruising or localized skin reactions at heparin injection sites	1% – 3% of patients	Outpatient oral antibiotic therapy (e.g., doxycycline); rotation of subcutaneous injection sites and cold compress application
Rare / Serious	Uterine perforation during operative hysteroscopy; severe pelvic inflammatory disease (PID); heparin-induced thrombocytopenia (HIT); major maternal bleeding complications	<0.5% of procedures/cases	Immediate surgical laparoscopy if perforation is complicated; broad-spectrum IV antibiotics; prompt discontinuation of heparin and conversion to non-heparin anticoagulants

Long-term safety data for antithrombotic therapies (low-dose aspirin combined with low-molecular-weight heparin) in patients with verified antiphospholipid syndrome show no increased risk of congenital fetal anomalies, though minor maternal bleeding rates (such as epistaxis or injection site hematomas) are increased (ESHRE 2023).

13. Lifestyle and Behavioural Considerations

Evidence-based lifestyle modifications play an important supportive role alongside medical protocols in optimizing uterine and systemic reproductive health.

Clinically recognized factors include:

• Body Mass Index (BMI) Optimization: Both low maternal BMI (<18.5 kg/m²) and elevated maternal BMI (>25–30 kg/m²) are associated with increased miscarriage rates. Achieving a balanced BMI through nutritional guidance improves metabolic stability and endometrial receptivity (ESHRE 2023).
• Tobacco and Nicotine Cessation: Cigarette smoking introduces toxic compounds that induce placental oxidative stress, vasoconstriction, and impaired trophoblast invasion. Complete cessation of tobacco and nicotine products is recommended.
• Alcohol and Caffeine Moderation: High daily alcohol intake is linked to increased pregnancy loss risk. High caffeine consumption (>200–300 mg daily, equivalent to two standard cups of coffee) should be reduced during pre-conception and early pregnancy.
• Occupational and Environmental Exposure: Exposure to heavy metals, organic solvents, ionizing radiation, and endocrine-disrupting chemicals should be minimized in early pregnancy.
• Periconceptional Folic Acid Supplementation: Standard daily folic acid supplementation (400–800 mcg) is initiated pre-conceptionally to prevent neural tube defects, with high-dose folate reserved for specific metabolic or medication-related indications.

14. How Outcomes Are Measured

Clinical success within a recurrent pregnancy loss clinic is evaluated using standard primary and secondary clinical endpoints.

Key outcome measures include:

• Cumulative Live Birth Rate (Primary Endpoint): The percentage of couples who achieve a live birth in subsequent pregnancies following diagnostic evaluation and targeted care.
• Reduction in Subsequent Miscarriage Rate: Demonstrating a lower loss rate compared to historic or untreated baselines.
• Diagnostic Etiology Yield: The proportion of couples in whom a clear, actionable biological cause for loss is identified (typically 45% to 50%).

Prognostic data indicate that even when standard diagnostic evaluations yield completely normal findings (unexplained RPL), the overall prognosis for a live birth in a subsequent natural pregnancy remains high—ranging from 60% to 80% depending on female age and the total number of prior losses (ESHRE 2023; Kolte et al., 2021). Thus, reassurance and structured supportive early pregnancy care constitute a core medical intervention.

15. Recent Advances and Current Standard of Care

Over the past decade, management protocols in RPL clinics have shifted toward molecular diagnostics and high-precision monitoring.

Key advances include:

• Chromosomal Microarray Analysis (CMA) and Next-Generation Sequencing (NGS): Replacing traditional metaphase tissue karyotyping on miscarried tissue. CMA and NGS do not require live cell culture, eliminating culture failure rates and detecting sub-microscopic microdeletions and duplications.
• Three-Dimensional Ultrasound replacing Invasive Hysterosalpingography: 3D TVUS is now the gold standard non-invasive tool for diagnosing congenital uterine anomalies, avoiding radiation and dye exposure.
• De-escalation of Unproven Therapies: Modern international guidelines strongly advise against routine, unproven immunomodulatory treatments—such as intravenous immunoglobulin (IVIG), lymphocyte immunization therapy (LIT), and routine intralipid infusions—due to a lack of high-quality randomized controlled trial evidence and potential safety risks (ESHRE 2023; ASRM 2020).
• Targeted Luteal Phase Progesterone Protocols: Evidence from the landmark PRISM trial (Coomarasamy et al., NEJM 2019) has refined the use of vaginal micronized progesterone, confirming benefit specifically in women with early pregnancy bleeding and a history of recurrent miscarriage.

16. Common Myths and Misconceptions

Uncertainty surrounding pregnancy loss can foster misconceptions that increase patient anxiety. Below are evidence-based corrections to common myths.

Myth: Recurrent pregnancy loss is usually caused by physical exertion, lifting heavy objects, or emotional stress.
Reality: Clinical guidelines from ESHRE (2023) affirm that everyday physical activity, routine exercise, working, and short-term emotional stress do not cause pregnancy loss. Miscarriages are driven by biological, structural, hormonal, or genetic factors.

Myth: Complete bed rest during early pregnancy prevents miscarriage in patients with a history of loss.
Reality: Randomized studies show that strict bed rest does not lower miscarriage rates and increases the risk of venous thromboembolism, bone demineralization, and psychological distress (ACOG 2018).

Myth: Proceeding directly to IVF automatically fixes recurrent pregnancy loss.
Reality: In vitro fertilization (IVF) bypasses mechanical tubal issues and allows embryonic screening, but it does not address maternal endocrine, uterine cavity, or antiphospholipid abnormalities. A systematic diagnostic evaluation is essential before initiating IVF (ASRM 2020).

Myth: Inherited thrombophilia testing is necessary for all patients who experience recurrent miscarriage.
Reality: Updated guidelines (ESHRE 2023; ASRM 2020) advise against routine screening for inherited thrombophilia (such as Factor V Leiden or Prothrombin mutations) in RPL patients without a personal or family history of thrombosis, as anticoagulation does not improve live birth rates in these cases.

Myth: Testing miscarried tissue is unnecessary because nothing can be done with the results.
Reality: Genetic testing on miscarried tissue (via CMA or NGS) determines whether a loss was due to a random numerical chromosome error (sporadic aneuploidy) or a potential parental structural genetic rearrangement, guiding future treatment planning.

Myth: Intravenous immunoglobulin (IVIG) and lipid infusions are proven treatments for unexplained RPL.
Reality: Current practice guidelines from ESHRE, ACOG, and ASRM advise against routine administration of IVIG or lipid infusions outside of ethical, approved clinical trials due to unproven efficacy and potential adverse effects.

Myth: Progesterone supplementation guarantees pregnancy preservation for every woman with RPL.
Reality: Progesterone benefit is demonstrated specifically in patients presenting with early pregnancy bleeding and a history of recurrent miscarriage (PRISM trial). It is not a universal cure for losses caused by chromosomal or structural defects.

17. Frequently Asked Questions

What defines a recurrent pregnancy loss clinic?

A recurrent pregnancy loss clinic is a specialized reproductive medicine unit focused on evaluating and treating couples who have experienced two or more failed pregnancies. Staffed by subspecialists, these clinics perform targeted genetic, anatomical, endocrine, and immunologic investigations to guide personalized care.

At what point should a couple seek evaluation at an RPL clinic?

Evaluation is recommended after two consecutive or non-consecutive clinical pregnancy losses confirmed by ultrasound or tissue examination. Women aged 35 or older or individuals with a history of late fetal loss may seek evaluation after a single loss, as advised by ASRM guidelines.

What diagnostic tests are routinely performed during the initial visit?

The diagnostic workup includes parental blood karyotyping, thyroid function panels (TSH, anti-TPO), antiphospholipid antibody screening (lupus anticoagulant, anticardiolipin, anti-beta-2-glycoprotein I), and detailed uterine cavity imaging using 3D transvaginal ultrasound or saline infusion sonohysterography.

How does a uterine septum cause recurrent pregnancy loss?

A uterine septum is a congenital band of fibromuscular tissue dividing the uterine cavity. Because the septum has poor blood supply, an embryo that implants on it cannot access adequate nutrients and oxygen, leading to early pregnancy loss. Surgical resection restores normal cavity architecture.

Is genetic testing of miscarried tissue always necessary?

Genetic testing of miscarried tissue using chromosomal microarray analysis (CMA) is recommended whenever feasible. Identifying a numerical chromosomal abnormality explains the specific loss event and reassures the couple that maternal physical or structural conditions were not the primary cause.

What treatment is prescribed for antiphospholipid syndrome (APS)?

Patients diagnosed with APS are treated with pre-conception low-dose aspirin (75–100 mg daily) combined with prophylactic low-molecular-weight heparin starting upon a positive pregnancy test. This combined regimen reduces microvascular thrombosis and improves live birth rates (ESHRE 2023).

Can male partner factors contribute to recurrent pregnancy loss?

Yes, male factors can contribute to pregnancy loss. Beyond parental chromosomal translocations, elevated sperm DNA fragmentation levels can impair embryonic development and increase loss rates. Male partner evaluation is increasingly included in comprehensive RPL protocols.

What is the clinical role of progesterone in managing RPL?

Progesterone supports decidualization of the uterine lining and early embryonic attachment. High-quality trial data (PRISM trial) demonstrate that empiric vaginal micronized progesterone therapy improves live birth rates in women presenting with early pregnancy bleeding who have a history of recurrent miscarriage.

How long should couples wait to attempt conception after an RPL evaluation?

Couples can usually attempt conception once diagnostic blood panels and cavity evaluations are complete, typically within 1 to 2 menstrual cycles. If hysteroscopic surgery is performed, clinicians advise waiting 1 to 2 cycles to allow adequate endometrial healing.

What is unexplained recurrent pregnancy loss?

Unexplained RPL refers to cases where comprehensive diagnostic testing—including genetic, anatomical, endocrine, and antithrombotic evaluations—yields entirely normal results. Unexplained RPL occurs in roughly 50% of evaluated patients, but overall prognosis for future live birth remains high with supportive care.

What is the success rate for subsequent pregnancies after RPL evaluation?

Overall cumulative live birth rates following management at an RPL clinic range between 60% and 80%, depending on female age, underlying etiology, and total number of prior losses. Targeted therapy for conditions like APS or uterine septa significantly improves pregnancy outcomes.

Are immunomodulatory therapies like IVIG recommended for RPL?

No, international clinical practice guidelines from ESHRE, ASRM, and ACOG advise against routine administration of intravenous immunoglobulin (IVIG) or intralipid infusions for RPL due to a lack of high-level evidence supporting efficacy and potential safety risks.

How does supportive care in early pregnancy impact outcomes?

Structured supportive care—including early, frequent transvaginal ultrasound surveillance, clear clinical guidance, and empathetic reassurance—is associated with reduced anxiety and improved pregnancy continuation rates in patients with a history of recurrent loss.

Is inherited thrombophilia screening routinely recommended?

Routine screening for inherited thrombophilic mutations (such as Factor V Leiden or Prothrombin gene mutations) is no longer recommended for all RPL patients, as systematic studies show that prophylactic anticoagulation does not improve live birth outcomes in these individuals unless a personal history of venous thrombosis is present.